Top Banner Top Banner

Antiangiogenic Treatments
Drugs that block tumor angiogenesis are altering the treatment landscape for many cancer types and providing new hope for patients with advanced cancer. In lung cancer, antiangiogeic agents are being used and tested primarily in patients with non-small cell lung cancer (NSCLC), the predominant type. Antiangiogenic cancer agents target VEGF and other angiogenic growth factors, and include the monoclonal antibody bevacizumab (Avastin®) and a number of other drugs in clinical trials.


Last updated July 15, 2011